Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

Y0001006

Dydrogesterone impurity B

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Pregna-4,6-diene-3,20-dione

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C21H28O2
Número CAS:
Peso molecular:
312.45
Código UNSPSC:
41116107
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

dydrogesterone

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

InChI

1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1

chave InChI

JGMOKGBVKVMRFX-LEKSSAKUSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Dydrogesterone impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificados de análise (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

A J Scheen et al.
Revue medicale de Liege, 66(4), 209-214 (2011-06-07)
Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is
Xiao-Dong Fu et al.
Molecular human reproduction, 18(1), 44-51 (2011-10-06)
Clinical observations and basic studies show that progesterone and progestins have a variable influence on endothelial function. Dydrogesterone (DG) is a widely used progestin, but its endothelial actions have not been thoroughly assessed. In this study, we investigated the effects
A R Genazzani et al.
Climacteric : the journal of the International Menopause Society, 14(6), 661-668 (2011-09-29)
Sexual desire is affected by endocrine and psychosocial factors. Menopausal hormonal changes are relevant to the causes of sexual dysfunction during reproductive aging. To evaluate the effects of different types of hormonal replacement therapy (HRT) on sexual function, frequency of
V M Kuba et al.
Climacteric : the journal of the International Menopause Society, 16(1), 54-61 (2012-05-30)
To evaluate the influence of dydrogesterone on estimated cardiovascular risk of users of hormone replacement therapy (HRT) (with percutaneous 17β-estradiol in monotherapy and in combination with dydrogesterone) and HRT non-users through the Framingham score tool for a period of 2
M V Suknovalova et al.
Eksperimental'naia i klinicheskaia farmakologiia, 76(7), 24-26 (2013-09-07)
It has been shown that specific binding of dydrogesterone with progesterone receptors in blood mononuclear cells of the patients included in the programs of in vitro fertilization, varies from 0 to 298%, thus at 38% of women dydrogesterone concedes to

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica